BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

Rhea-AI Summary

BioCardia (NASDAQ: BCDA) announced that echocardiography data from the CardiAMP HF trial has been accepted for a Late Breaking Clinical Trial Oral Presentation at Technology and Heart Failure Therapeutics (THT) in Boston, March 2-4, 2026.

Dr. Amish Raval will present the late-breaking echocardiography results on March 2 at 2:00 PM ET, focusing on autologous cell therapy and ventricular remodeling in chronic ischemic HFrEF patients selected for favorable cell characteristics.

News Market Reaction

-4.13%

3 alerts

-4.13% News Effect

+9.7% Peak Tracked

-$498K Valuation Impact

$12M Market Cap

1.4x Rel. Volume

On the day this news was published, BCDA declined 4.13%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.7% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $498K from the company's valuation, bringing the market cap to $12M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 2–4 Presentation time: 2pm EST

2 metrics

Conference dates March 2–4 Technology and Heart Failure Therapeutics (THT) Meeting 2026 in Boston

Presentation time 2pm EST THT Late Breaking Clinical Trial Oral Presentation on March 2

Market Reality Check

Price: $1.25 Vol: Volume 42,436 is 35% belo...

low vol

$1.25 Last Close

Volume Volume 42,436 is 35% below 20-day average 65,215 (relative volume 0.65). low

Technical Price $1.21 is trading below 200-day MA $1.78, about 62.19% below 52-week high $3.20 and 21% above 52-week low $1.00.

Peers on Argus

BCDA was down 1.63% while peers showed mixed moves: ADAP -17.57%, PHIO -1.29%, I...

BCDA was down 1.63% while peers showed mixed moves: ADAP -17.57%, PHIO -1.29%, IMRN -2.07% versus PHGE +8.73% and BCTX +3.95%, suggesting stock-specific trading rather than a broad biotech move.

Historical Context

5 past events · Latest: Dec 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 16	Regulatory consultation	Positive	-1.5%	PMDA allowed CardiAMP HF for ischemic HFrEF to enter formal consultation.
Dec 03	Board change	Positive	+3.6%	New director added with commercial and regulatory cardiology experience.
Dec 01	Conference presentation	Neutral	-4.1%	Planned presentation on intramyocardial cell therapy at CSI Focus congress.
Nov 24	Leadership hire	Positive	+0.7%	Appointment of VP of Quality with 25+ years in medical and digital health.
Nov 12	Earnings and update	Neutral	-3.1%	Q3 2025 results with $6.0M financing and multiple CardiAMP/CardiALLO updates.

Pattern Detected

Recent news has drawn mixed reactions: clinical and regulatory updates sometimes saw negative moves, while governance and leadership changes tended to align positively with price.

Recent Company History

Over the past few months, BioCardia highlighted progress across clinical, regulatory, and corporate fronts. On Dec 16, 2025, Japan’s PMDA allowed CardiAMP for ischemic HFrEF to advance to a formal clinical consultation. Earlier in December, BCDA announced a new director with interventional cardiology and device experience and participation in a heart failure devices congress. Leadership was strengthened with a new Vice President of Quality, and Q3 2025 results detailed a $6.0M financing, ongoing CardiAMP HF II Phase 3 enrollment, and positive early CardiALLO safety findings. Today’s late-breaking echocardiography presentation continues this cardiology-focused trajectory.

Market Pulse Summary

This announcement highlights acceptance of late-breaking echocardiography results from the CardiAMP ...

Analysis

This announcement highlights acceptance of late-breaking echocardiography results from the CardiAMP HF trial for oral presentation at the THT Meeting on March 2. It follows recent progress with Japan’s PMDA, ongoing CardiAMP HF II Phase 3 enrollment, and early CardiALLO safety signals. Investors may focus on how these imaging data complement prior survival and functional outcomes, as well as the company’s ability to advance regulatory discussions and potential commercialization steps.

Key Terms

echocardiography, autologous cell therapy, ventricular remodeling, hfreF, +1 more

5 terms

echocardiography medical

"announced echocardiography data for the CardiAMP Cell Therapy for the treatment"

An echocardiography is a noninvasive test that uses sound waves to create moving images of the heart, showing its size, pumping strength and how the valves work—think of it as an ultrasound camera for the heart. Investors care because these images provide objective measures used to diagnose heart disease, guide treatment decisions, support clinical-trial endpoints and drive demand for medical devices and services, which affects revenue and reimbursement outlooks.

autologous cell therapy medical

"“Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic"

Autologous cell therapy uses a patient’s own cells, taken out, sometimes modified or multiplied, and then returned to the same person to treat disease or repair tissue. It matters to investors because using a person’s own cells can lower the chance of immune rejection and change the regulatory and clinical risk profile, but it also creates high, customized manufacturing and delivery costs and limits how easily the therapy can be scaled — like bespoke tailoring versus off‑the‑rack clothing.

ventricular remodeling medical

"May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients"

Ventricular remodeling is the physical change in size, shape, or function of the heart’s main pumping chambers after injury or chronic stress, like scar tissue forming or walls thinning. Investors care because remodeling drives long‑term patient outcomes and determines demand for drugs, medical devices, and procedures aimed at preventing or reversing that change; it also influences clinical trial endpoints, regulatory decisions, and healthcare costs.

hfreF medical

"Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable"

A form of chronic heart failure in which the heart’s main pumping chamber cannot push out blood as effectively as normal, measured by a lower percentage called the ejection fraction. Imagine a water pump that can no longer move as much water each cycle; the body gets less blood and organs may suffer. Investors care because the condition drives demand for drugs, medical devices and clinical trials, and outcomes, approvals or reimbursement changes can materially affect company revenues and valuations.

late breaking clinical trial technical

"Late Breaking Echocardiography Results from the CardiAMP HF trial.” Presentation"

A late-breaking clinical trial is an important study result released on short notice or later than usual because the findings are considered especially newsworthy or potentially decisive for a treatment’s future. For investors it’s like a surprise exam score: the new data can rapidly change expectations about a drug’s safety, effectiveness, regulatory approval and market potential, so company valuations and trading can move sharply when these results are announced.

AI-generated analysis. Not financial advice.

SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts.

On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal Investigator.

Presentation Title: “Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial.”

Presentation Session: THT Late Breaking Clinical Trial Oral Presentation on March 2 at 2pm EST.

About CardiAMP Autologous Cell Therapy

Granted FDA Breakthrough designation, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure intended to increase capillary density and reduce tissue fibrosis of myocardial tissue to address microvascular dysfunction. Clinical development of the CardiAMP Cell Therapy for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Centers for Medicare and Medicaid Services (CMS). CAUTION - Limited by United States law to investigational use. 

About BioCardia^® 

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP^® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph^® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.

Forward Looking Statements 

This press release contains forward-looking statements that are subject to risks and uncertainties. Forward-looking statements include, among other things, the presentation of data and future conferences, the protection of the Company’s intellectual property estate, and references to the Company’s investigational product candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors,” and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: 
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

FAQ

What did BioCardia (BCDA) announce about the CardiAMP HF echocardiography data for THT 2026?

BioCardia announced acceptance of CardiAMP HF echocardiography data for a Late Breaking Clinical Trial Oral Presentation. According to the company, the data will be presented March 2, 2026 at 2:00 PM ET during the THT meeting in Boston.

Who will present the CardiAMP HF late-breaking echocardiography results for BioCardia (BCDA) at THT?

Dr. Amish Raval will deliver the presentation as National Co-Principal Investigator. According to the company, he is scheduled to present the late-breaking echocardiography results on March 2 at 2:00 PM ET.

When and where will BioCardia (BCDA) present the CardiAMP HF late-breaking echocardiography results?

The presentation is set for March 2, 2026 at 2:00 PM ET in Boston, Massachusetts. According to the company, the session is part of the THT meeting taking place March 2-4, 2026.

What is the focus of the CardiAMP HF THT presentation by BioCardia (BCDA)?

The presentation examines autologous cell therapy and ventricular remodeling in chronic ischemic HFrEF patients selected for favorable cell characteristics. According to the company, echocardiography results support that focus and form the late-breaking talk.

Does the announcement from BioCardia (BCDA) include specific CardiAMP HF trial results or numeric data?

No specific numeric results or detailed metrics were included in the announcement. According to the company, only that echocardiography data was accepted for a late-breaking oral presentation at THT.

How can investors learn more about the CardiAMP HF presentation from BioCardia (BCDA) at THT?

Investors should follow the THT meeting schedule and BioCardia communications for the March 2 presentation details. According to the company, the echocardiography results will be presented during the THT Late Breaking Clinical Trial session.